A detailed history of Rock Springs Capital Management LP transactions in Argenx Se stock. As of the latest transaction made, Rock Springs Capital Management LP holds 233,500 shares of ARGX stock, worth $146 Million. This represents 4.31% of its overall portfolio holdings.

Number of Shares
233,500
Previous 229,250 1.85%
Holding current value
$146 Million
Previous $98.6 Million 28.45%
% of portfolio
4.31%
Previous 3.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $1.85 Million - $2.35 Million
4,250 Added 1.85%
233,500 $127 Million
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $10.1 Million - $15.1 Million
-29,750 Reduced 11.49%
229,250 $87.2 Million
Q3 2023

Nov 14, 2023

SELL
$369.35 - $548.43 $33.6 Million - $49.9 Million
-91,000 Reduced 26.0%
259,000 $127 Million
Q1 2022

May 16, 2022

BUY
$254.45 - $351.06 $8.91 Million - $12.3 Million
35,000 Added 11.11%
350,000 $110 Million
Q2 2021

Aug 16, 2021

BUY
$257.11 - $319.92 $3.86 Million - $4.8 Million
15,000 Added 5.0%
315,000 $94.8 Million
Q1 2021

May 17, 2021

BUY
$268.3 - $380.31 $3.35 Million - $4.75 Million
12,500 Added 4.35%
300,000 $82.6 Million
Q2 2020

Aug 14, 2020

BUY
$127.44 - $232.72 $5.1 Million - $9.31 Million
40,000 Added 16.16%
287,500 $64.8 Million
Q4 2019

Feb 14, 2020

BUY
$106.59 - $164.21 $7.01 Million - $10.8 Million
65,800 Added 36.21%
247,500 $39.7 Million
Q1 2019

May 15, 2019

BUY
$98.85 - $134.59 $365,745 - $497,983
3,700 Added 2.08%
181,700 $22.7 Million
Q4 2018

Feb 14, 2019

BUY
$63.81 - $109.82 $829,530 - $1.43 Million
13,000 Added 7.88%
178,000 $17.1 Million
Q3 2018

Nov 14, 2018

BUY
$75.5 - $96.63 $2.74 Million - $3.5 Million
36,250 Added 28.16%
165,000 $12.5 Million
Q2 2018

Aug 14, 2018

BUY
$74.84 - $100.16 $9.64 Million - $12.9 Million
128,750 New
128,750 $10.7 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.